Urothelial Cancer: Current First-line Therapy Guidelines and Recommendations

Download these slides from a live Webinar to gain expert insight on the optimal treatment options for first-line therapy for patients with metastatic urothelial cancer, including the latest evidence from ASCO GU 2021.
Matthew Galsky, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.56 MB
Released: February 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Pfizer, Inc. and EMD Serono

Related Content

Slides on checkpoint inhibitors in first-line, second-line, and maintenance settings for urothelial carcinoma, from Clinical Care Options (CCO)

Cora N. Sternberg, MD, FACP Released: February 26, 2021

Slides on erdafitinib, enfortumab vedotin, and sacituzumab govitecan for progressive urothelial carcinoma, from Clinical Care Options (CCO)

Petros Grivas, MD, PhD Released: February 26, 2021

Comentario de un experto sobre las terapias de combinación que utilizan inhibidores de PARP más otros agentes en el cáncer de próstata avanzado de Clinical Care Options (CCO).

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: February 25, 2021

Commentaire des experts sur les associations thérapeutiques utilisant les inhibiteurs PARP et d'autres agents dans le traitement du cancer avancé de la prostate, extrait de Clinical Care Options (CCO)

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: February 25, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue